Wegovy obesity drug supply cut in US due to high demand.
Novo Nordisk is cutting the supply of starter doses of its obesity drug Wegovy in the U.S. due to surging demand, but is ramping up supply every day and plans to increase production in the coming years. The drug has received regulatory approval in a number of countries outside the U.S., including the U.K., but the company plans to progress cautiously. Wegovy is one of a number of drugs that have been grabbing headlines amid a growing push to tackle rising global obesity rates.